Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III afamelanotide implant trial in polymorphic light eruption
NL-OMON35045Phase 3Active, not recruiting
- Sponsor
- Clinuvel Pharmaceuticals
- Start
- May 2010
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in polymorphic light eruption (PMLE) comparing Afamelanotide implant with Placebo implant (2 arms). Primary endpoint: Severity of PLE-related pruritus. Started May 2010; status: active, not recruiting.
02
Drugs
Afamelanotide
03
Conditions
polymorphic light eruption (PMLE)
Beyond the preview
Go deeper on NL-OMON35045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35045.